论文部分内容阅读
美国达勒姆消息:测定卵巢癌病人血中称作CA125的一种大分子物质水平,能早期预示化疗治疗是否无效。据此地Duke大学的Duke综合癌症中心的Robert Bast医师称,盆腔肿瘤病人CA125水平升高表明是癌,不是良性病变。 Bast说:“CA125分子的脱落量能说明癌细胞是由机体排除,抑或治疗后因抗药仍残存。”测定卵巢癌病人的CA125水平,其升高或降低可说明肿瘤是在增大还是在缩小,准确率达80％以上。对于卵巢癌患者进行此种检查和测定非常
Durham, United States: The determination of a macromolecular substance called CA125 in the blood of patients with ovarian cancer can predict early whether chemotherapy treatment is ineffective. According to Dr. Robert Bast from the Duke Comprehensive Cancer Center at Duke University, elevated levels of CA125 in patients with pelvic cancer are cancers, not benign lesions. Bast said: “The shedding amount of CA125 can indicate that the cancer cells were eliminated by the body, or they remain because of drug resistance after treatment.” The CA125 level in ovarian cancer patients is measured. The increase or decrease of CA125 can indicate whether the tumor is increasing or not. Reduced, accurate rate of more than 80%. This kind of examination and measurement is very important for patients with ovarian cancer